The X-linked dominant Conradi-Hünermann-Happle (CDPX2, MIM 302960) syndrome belongs to the rare, heterogeneous group of diseases called chondrodysplasia punctata. The disease has been connected recently with deficiency of 3beta-hydroxysteroid-Delta8-Delta7-isomerase (also called emopamil-binding protein, EBP), catalysing an intermediate step in the conversion of lanosterol to cholesterol (1, 2). We report a case of CDPX2 with a new missense mutation (C-->G 439) in exon 4, leading to a R147G aminoacid substitution in the EBP.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1034/j.1600-0625.2001.100409.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
SMAP3-ID for Identification of Endogenous Protein-Protein Interactions Reveals Regulation of Mitochondrial Activity by Lamins.
JACS Au
January 2025
Program in Chemical Biology, Department of Chemical Physiology and Biochemistry, Proteomics Shared Resources, Knight Cancer Institute, Department of Neurology, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, Portland, Oregon 97239, United States.
Proteins regulate biological functions through the formation of distinct protein complexes. Identification and characterization of these protein-protein interactions are critical to deciphering their mechanism of action. Different antibody-based or cross-linking-based methods have been developed to identify the protein-protein interactions.
View Article and Find Full Text PDFIdentification of sulfonylated indolo[1,2-]quinolines as EGFR tyrosine kinase inhibitors.
RSC Adv
January 2025
Department of Chemistry, Center of Excellence for Innovation in Chemistry (PERCH-CIC), Faculty of Science, Mahidol University Rama VI Road Bangkok 10400 Thailand
Two series of indolo[1,2-]quinolines (IQs), comprising six 6-trifluoromethylthio indolo[1,2-]quinolines and nine 6-arenesulfonyl indolo[1,2-]quinolines, were screened for their inhibitory activity against EGFR tyrosine kinase (EGFR-TK) using the ADP-Glo™ kinase assay. Among the 15 IQs screened, four compounds exhibited cytotoxic activity against a lung cancer cell line (A549) that was as potent as the known drug afatinib with lower cytotoxicity in Vero cells. In addition, while they displayed cytotoxic activity against a head and neck squamous cell carcinoma cell line (SCC cells), they were inactive against a colorectal cancer cell line (LS174T cells).
View Article and Find Full Text PDFOngoing invasions by American bullfrogs and red-eared sliders in the Republic of Korea.
Anim Cells Syst (Seoul)
January 2025
Division of EcoScience, Ewha Womans University, Seoul, Republic of Korea.
Invasive species can be unpredictable in their ability to adapt and spread across novel landscapes. American bullfrogs () and red-eared sliders () have become invasive in South Korea since their introduction in the 1970s through the food and pet trades. One of the first steps to their population regulations is to determine each species' distribution in the country, which will allow for the identification of at-risk areas.
View Article and Find Full Text PDFMolecular simulation of newly designed Mannich-based ciprofloxacin derivative as the promising scaffold for dihydropteroate synthase and DNA gyrase inhibitor.
J Biomol Struct Dyn
January 2025
ICMR-Regional Medical Research Centre, Department of Health Research, Ministry of Health and Family Welfare, Government of India, Bhubaneswar, India.
The increasing incidence of bacterial infections has led to rise in antimicrobial resistance (AMR), a significant concern in public health across the globe. Henceforth, there is an urgency to address the AMR catastrophe, including developing new antibiotics, promoting the appropriate use of existing antibiotics, and investing more in research and development. Development of potent antibiotic derivatives is the call of the day.
View Article and Find Full Text PDFAdeno-associated viral vectors for modeling Parkinson's disease in non-human primates.
Neural Regen Res
January 2025
CNS Gene Therapy Department, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.
The development of clinical candidates that modify the natural progression of sporadic Parkinson's disease and related synucleinopathies is a praiseworthy endeavor, but extremely challenging. Therapeutic candidates that were successful in preclinical Parkinson's disease animal models have repeatedly failed when tested in clinical trials. While these failures have many possible explanations, it is perhaps time to recognize that the problem lies with the animal models rather than the putative candidate.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!